Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform

News
Multimedia
Publication
Conferences
Resources
Subscribe
Webcasts
Event Calendar

Spotlight -

Downstream Processing|

Upstream Processing

Thomas S. Vedvick

Thomas S. Vedvick is the director of process sciences at the Infections Disease Research Institute, Seattle, WA

Articles by Thomas S. Vedvick

Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs

ByRyan C. Anderson,Thomas S. Vedvick,Timothy S. Dutill,James Chesko,Christopher B. Fox,Steven G. Reed

October 2nd 2010

Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).

The Effect of Limiting Phosphate Using the HMS174 Cell Line

ByThomas S. Vedvick,Garner G. Moulton

July 1st 2010

The HMS174 strain, in the absence or presence of excess phosphate, can metabolize acetate efficiently.

Latest Updated Articles

The Effect of Limiting Phosphate Using the HMS174 Cell Line
July 1st 2010
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs
October 2nd 2010

Trending on BioPharm International

Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development

ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months

enGene Plans Year-End BLA for Detalimogene in BCG-Unresponsive NMIBC

Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA